Potential of China’s first KRAS G12C inhibitor Dupert in NSCLC

9 September 2024

Chinese companies Innovent Biologics (HKEX: 01801) and GenFleet have recently secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib), the country’s first KRAS G12C inhibitor for advanced non-small cell lung cancer (NSCLC) in adults who have undergone prior systemic therapy.

This breakthrough therapy addresses a challenging mutation, offering a critical new treatment option for patients with limited alternatives, says pharma analytics firm GlobalData.

Innovent and GenFleet Therapeutics entered into an exclusive license agreement in September 2021 for the development and commercialization of fulzerasib in China, with option-in rights for markets outside the country. Fulzerasib, in combination with cetuximab, is currently in Phase II trials for NSCLC in Europe in collaboration with Germany’s Merck KGaA (MRK: DE). Fulzerasib is also in clinical development for colorectal cancer (CRC). It is in Phase III trials in China and the US for CRC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK